Literature DB >> 16310933

Relationship of NKX3.1 and MYC gene copy number ratio and DNA hypomethylation to prostate carcinoma stage.

Roland Kindich1, Andrea R Florl, Jörn Kamradt, Jan Lehmann, Mirko Müller, Bernd Wullich, Wolfgang A Schulz.   

Abstract

OBJECTIVE: High stage prostate cancers have been reported to frequently harbor chromosome 8 alterations and hypomethylation of LINE-1 retrotransposons. The potential of these parameters for molecular staging of prostate carcinoma was investigated.
METHODS: High molecular weight DNA was extracted from 63 carcinoma tissues (22 pT2, 38 pT3, 3 pT4). Chromosome 8 alterations were followed by determining the ratio of NKX3.1 (at 8p21) to MYC (at 8q24) gene copy numbers (NKX3.1:MYC ratio) using a new real-time PCR technique. LINE-1 hypomethylation was quantified by Southern blot analysis.
RESULTS: In 42 carcinomas NKX3.1 copy numbers were altered, with decreases in 32 cases. Copy numbers of MYC were increased in 38 cases and diminished in four. The NKX3.1:MYC ratio was altered in 45 specimens, with a decrease in all but two. NKX3.1 loss was associated with tumor stage (p<0.03) and MYC gain with Gleason score (p<0.03). The NKX3.1:MYC ratio was highly significantly associated with tumor stage (p<0.002), displaying 66% sensitivity and 87% specificity. LINE-1 hypomethylation was related (p<0.004) to tumor stage, but exhibited lower sensitivity (59%) and specificity (77%).
CONCLUSION: A straightforward PCR technique detecting chromosome 8 alterations might be useful to predict which prostate cancers are organ-confined while determination of hypomethylation appears to be somewhat less well suited.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16310933     DOI: 10.1016/j.eururo.2005.09.012

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  7 in total

Review 1.  Global DNA hypomethylation in prostate cancer development and progression: a systematic review.

Authors:  R Zelic; V Fiano; C Grasso; D Zugna; A Pettersson; A Gillio-Tos; F Merletti; L Richiardi
Journal:  Prostate Cancer Prostatic Dis       Date:  2014-11-11       Impact factor: 5.554

2.  Long interspersed nuclear element-1 hypomethylation in cancer: biology and clinical applications.

Authors:  Nakarin Kitkumthorn; Apiwat Mutirangura
Journal:  Clin Epigenetics       Date:  2011-04-10       Impact factor: 6.551

Review 3.  Epigenetics of prostate cancer: beyond DNA methylation.

Authors:  W A Schulz; J Hatina
Journal:  J Cell Mol Med       Date:  2006 Jan-Mar       Impact factor: 5.310

4.  Cause and consequences of genetic and epigenetic alterations in human cancer.

Authors:  B Sadikovic; K Al-Romaih; J A Squire; M Zielenska
Journal:  Curr Genomics       Date:  2008-09       Impact factor: 2.236

5.  Prostate cancer epigenetics: a review on gene regulation.

Authors:  Lena Diaw; Karen Woodson; John W Gillespie
Journal:  Gene Regul Syst Bio       Date:  2007-12-11

6.  In vitro analysis of integrated global high-resolution DNA methylation profiling with genomic imbalance and gene expression in osteosarcoma.

Authors:  Bekim Sadikovic; Maisa Yoshimoto; Khaldoun Al-Romaih; Georges Maire; Maria Zielenska; Jeremy A Squire
Journal:  PLoS One       Date:  2008-07-30       Impact factor: 3.240

7.  Factor interaction analysis for chromosome 8 and DNA methylation alterations highlights innate immune response suppression and cytoskeletal changes in prostate cancer.

Authors:  Wolfgang A Schulz; Adrian Alexa; Volker Jung; Christiane Hader; Michèle J Hoffmann; Masanori Yamanaka; Sandy Fritzsche; Agnes Wlazlinski; Mirko Müller; Thomas Lengauer; Rainer Engers; Andrea R Florl; Bernd Wullich; Jörg Rahnenführer
Journal:  Mol Cancer       Date:  2007-02-05       Impact factor: 27.401

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.